Boston Scientific CEO Mike Mahoney highlighted the commercial success of Boston Scientific’s Watchman left-atrial appendage closure devices during his presentation at the J.P. Morgan Healthcare conference on 12 January.
According to a preliminary report on the company’s fourth-quarter earnings, sales of Watchman devices – including the next-generation Watchman FLX...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?